Abstract
OBJECTIVE: To collect data and investigate the effects of Huangkui capsule (黄葵胶囊, HKC) on chronic kidney disease (CKD). METHODS: PubMed, Embase, Cochrane Library, and three Chinese databases (China National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database) were searched for articles published until October 2020. Randomized controlled trials (RCTs) of HKCs used for treating CKD were reviewed. Data were organized and analyzed using RevMan 5.3 software. RESULTS: HKC significantly lowered the blood urea nitrogen (BUN) level [mean difference (MD) = －2.26; 95% confidence interval (CI), －2.91 to －1.61], serum creatinine level (MD = －17.45; 95% CI, －22.29 to －12.60), and 24-h urine protein content (MD = －0.73; 95% CI, －1.00 to －0.46) and improved the glomerular filtration rate (GFR) (MD = 10.69; 95% CI, 5.57 to 15.81) and serum albumin level (MD = 2.20; 95% CI, 0.49 to 3.90). CONCLUSIONS: Our findings show that HKC could lower the BUN level, serum creatinine level, and 24-h urine protein content. HKC also improved GFR and serum albumin levels. However, high-quality RCTs in other countries with larger sample sizes are warranted to confirm these findings.